ABSTRACT
In the bone marrow (BM), hematopoietic stem cells (HSC) reside in specific niches near osteoblast-lineage cells at the endosteum. To investigate regulation of these endosteal niches, we studied mobilization of HSC into the bloodstream in response to granulocyte colonystimulating factor (G-CSF). We report that G-CSF mobilization rapidly depletes endosteal osteoblasts leading to suppressed endosteal bone formation and decreased expression of factors required for HSC retention and self-renewal. Importantly, G-CSF administration also depleted a population of trophic endosteal macrophages (osteomacs) that support osteoblast function. Osteomac loss, osteoblast suppression and HSC mobilization occurred concomitantly, suggesting that osteomac loss could disrupt endosteal niches. Indeed in vivo depletion of macrophages, in either macrophage Fas-induced apoptosis (Mafia) transgenic mice or by administration of clodronate-loaded liposomes to wild-type mice, recapitulated the i) loss of endosteal osteoblasts, ii) marked reduction of HSC-trophic cytokines at the endosteum, with iii) HSC mobilization into the blood as observed during G-CSF administration. Together these results establish that BM macrophages are pivotal to maintain the endosteal HSC niche and that the loss of such macrophages leads to the egress of HSC into the blood.
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INTRODUCTION
Hematopoietic stem cells (HSC) reside in bone marrow (BM) and produce all cells required to replenish the blood and immune systems; this process is tightly regulated to maintain a steady number of leukocytes, platelets and red cells in the blood. Individual HSC undergo one of several fates: quiescence, apoptosis, cycling either to self-renew, or to generate a more committed hematopoietic progenitor cell (HPC), or migration. These fates are largely controlled by specific local micro-environments ('niches') in which HSC and HPC reside.
While HSC niches were conceptualized in the 1970s 1 , it is only in recent years, with the advent of mouse genetic models and live microscopy, that precise locations and nature of HSC niches have been proposed. Recent microscopy studies have shown that quiescent longterm reconstituting HSC preferentially reside within 20µm of the interface between compact bone and BM (endosteum) and 10 µm (or 2 cell diameters) from osteoblasts [2] [3] [4] [5] , in poorly perfused regions of the BM. 6 Similarly, Lin -CD41 -Sca1 + KIT + CD48 -CD150 + HSC isolated from the femoral endosteal regions have higher long-term reconstitution potential than phenotypically identical HSC isolated from the central BM. 7 Functional studies support a role for osteoblast-lineage cells to maintain HSC in the BM in vivo. Transgenic mice with increased osteoblast function have more HSC in the BM 8, 9 whereas targeted ablation of osteoblasts in vivo results in progressive loss of HSC from the BM 10 . Finally, targeted deletion in osteoprogenitors of Dicer-1, necessary for the maturation and processing of all microRNA, results in pancytopenia, exaggerated HSC proliferation, ineffective hematopoiesis and myelodysplasia 11 . Thus it appears that the endosteal region and osteoblast-lineage cells provide a unique environment necessary for HSC survival, quiescence, self-renewal, and contribution to long-term hematopoiesis 11,12 . Despite significant breakthroughs in the identification of cellular and molecular components of BM HSC niches, little is known of how these niches are regulated in vivo. To gain insights in the regulation of endosteal niches, we studied therapeutic mobilization of HSC. During mobilization, HSPC (HSC and HPC) are forced to migrate and circulate in the blood, allowing the harvest of large numbers of HSC from patients for transplantation 13, 14 .
Granulocyte colony-stimulating factor (G-CSF) is the most common mobilizing agent used in the clinic. While inhibition of endosteal osteoblasts has been reported during G-CSF treatment, the mechanisms leading to this inhibition remain unclear [15] [16] [17] . While a role of sympathetic nerves innervating the BM and the bone was proposed 16 , recent experiments using transplantation chimeras of wild-type and G-CSF receptor (GCSFR)-deficient mice For personal use only. on October 28, 2017. by guest www.bloodjournal.org From show that BM leukocytes are also required for osteoblast suppression and HSPC mobilization by G-CSF 17 .
We confirm that G-CSF rapidly and transiently ablates endosteal osteoblasts 17 and extend these observations by demonstrating a cessation of endosteal bone formation.
Strikingly, this depletion of endosteal osteoblasts and bone formation was accompanied by a loss of BM macrophages, particularly osteoblast-supportive endosteal macrophages (osteomacs). Furthermore, depletion of BM macrophages, in particular a novel CD11b + F4/80 + Ly6-G + phagocytic macrophage population, in two mechanistically unrelated in vivo models, was sufficient to suppress endosteal osteoblasts, inhibit expression of HSCsupportive cytokines at the endosteum, and elicit HSPC mobilization into the peripheral blood. This study reveals a critical role for BM macrophages in maintaining the endosteal HSC niche.
METHODS

Procedures were approved by the University of Queensland's Animal Experimentation Ethics
Committee.
G-CSF Mobilization
Dipeptidylpeptidase-1 (DPP-1) and GCSFR knock-out mice backcrossed into C57BL/6 were kindly provided by Dr C Pham and DC Link (Washington University, St Louis). All experiments were performed on 12-14 week-old skeletally mature C57BL/6 mice except G-CSF-treated control mice for protease concentration assays ( Figure 7A ) which were 129Sv.
To assess effects of G-CSF mobilization, mice were injected twice daily subcutaneously with 125µg/kg/injection recombinant human G-CSF (a kind gift of Amgen, Thousand Oaks, CA) or saline for up to 6 consecutive days. When required, osteoclast activity was blocked by a 6 day treatment with 20µg/kg/day subcutaneous injections of zoledronate (Zometa, Novartis Pharmaceuticals Australia, North Ryde, Australia) prior to sacrifice and G-CSF was administered twice subcutaneously at 125µg/kg for the last 3 days prior to sacrifice.
To assess bone formation during mobilization, G-CSF or saline was injected from day 0 to day 5 as described above. Calcein (Sigma Chemicals, St Louis, MO) was injected intraperitoneally at a dose of 20mg/kg on days 1 and 7. Xylenol orange (Sigma Chemicals)
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Macrophage depletion in vivo
In a first model, myeloid cells were depleted from skeletally mature Macrophage-Fas-Induced Apoptosis (Mafia) transgenic mice by daily intravenous retro-orbital injection of 10 mg/kg/day AP20817 ligand (generous gift from ARIAD Pharmaceuticals Inc, Cambridge, MA www.ariad.com/regulationkits) dissolved in 4% ethanol, 10% PEG-400, 1.7% Tween-20 18 . Controls were Mafia mice injected with vehicle alone and wild-type mice injected with AP20817 ligand. In a second model, clodronate (dichloromethylene bisphosphonate), a gift from Roche Diagnostics (Mannheim, Germany), was packaged into liposomes as previously described 19 .
Empty liposomes were prepared in the same conditions in PBS without clodronate.
Phagocytic macrophages were depleted in vivo by retro-orbitally injecting 250µL/25g clodronate-loaded liposome suspension every second day. Control mice were injected with an equivalent volume of saline or PBS-loaded liposomes.
Tissue harvesting and RNA extraction
At specified time-points, mice were anesthetized and 1mL blood collected into heparinized tubes by cardiac exsanguinations. Red cells were lysed from blood as previously described 20 .
Spleens were harvested, weighed and dissociated in PBS with 2% FCS. Cells and RNA from enriched central BM, and endosteal RNA were isolated from femurs as previously described 21 . Tibias were fixed in PBS containing 4% paraformaldehyde overnight at 4°C and stored in 70% ethanol until embedding in methacrylate 22 for undecalcified bone histomorphometry, or decalcified in 14% EDTA and embedded in paraffin for immunohistochemistry and enzyme staining.
Quantitative real-time RT-PCR (RT-qPCR)
RNA was extracted with Trizol, precipitated, DNase treated and reverse transcribed using random hexamers. RT-qPCR with SYBR green for osteocalcein, osterix, KL, Ang-1, VEcadherin and fibronectin or using Taqman probes (labeled 5'with 6-carboxyfluorescein (FAM) and 3' with blackhole quencher-1 (BHQ-1)) for Runx2 and PTHR1 were performed following manufacturer's instructions (ABI systems, Foster City, CA). Oligonucleotide sequences are shown in Table 1 . Primers were designed to cross intron-exon boundaries to not For personal use only. on October 28, 2017. by guest www.bloodjournal.org From amplify genomic DNA, with the exception of osterix that is encoded by a single exon. A PCR from each sample prior to reverse transcription confirmed absence of genomic DNA. RNA levels were standardized by parallel RT-qPCR using primers to the house-keeping gene β2microglobulin.
Histomorphometry
Tibial samples were embedded in methacrylate, and undecalcified 5μm sections were stained with toluidine blue and histomorphometry carried out in the trabecular bone of the proximal tibial secondary spongiosa using the Osteomeasure system (OsteoMetrics Inc, Decatur, GA) 22 . For mineral appositional rates, sections remained unstained and fluorochromes were visualized by epifluorescence microscopy 22 .
Calcein and xylenol orange mineralization fronts were visualized on a Zeiss LSM 510
Meta confocal laser scanning microscope. Calcein fluorescence was excited at 488nm with an Ar laser and emission detected through a 505-530nm filter whereas xylenol orange fluorescence was excited at 543nm with a He-Ne laser and emission detected through a 560nm filter. Each fluorophore was excited, scanned and acquired separately.
Cell counts and colony assays
Leukocytes were counted on a Sysmex KX-21 automated cell counter. For myeloid colony assays, cells were deposited in 35mm Petri dishes and covered with 1mL IMDM supplemented with 1.6% methylcellulose (high viscosity Methocell MC, Fluka), 35% FCS.
Optimal concentrations of mouse IL-3, IL-6 and soluble KL were added as conditioned media from stably transfected BHK cell lines. Colonies were counted after 10 days of culture.
Competitive repopulation assays
The content of mobilized blood samples in competitive repopulating HSC was determined in competitive repopulation assays. The day prior to blood harvest, recipient congenic B6.SJL CD45.1 + mice were lethally irradiated with 11.0Gy in two split doses 3 hours apart. 50µL blood samples from 4 mobilized CD45.2 + C57BL/6 mice were pooled within each treatment group and 50µL blood aliquots were taken from this pool and mixed with 200,000 competitive whole BM cells from untreated B6.SJL CD45.1 + in a total volume of 200µL, and injected retro-orbitally into each lethally irradiated recipient. Recipients were maintained with antibiotics for the first 3 weeks post-transplant and tail bled 16 weeks post-transplant to 
Flow cytometry
Following flushing with PBS, enriched central BM cells were pelleted at 370xg for 5 minutes at 4°C and resuspended in CD16/CD32 hybridoma 2.4G2 supernatant to block IgGFc receptors except for myeloid progenitor stains.
HSC were stained with the biotinylated lineage antibody cocktail (CD3, CD5, B220, CD11b, Gr-1, Ter119) and biotinylated CD41 together with SAV-PB, Sca-1-PECY7, KIT-APC, CD48-FITC and CD150-PE.
Mature myeloid cells were stained with CD11b-PECY7, anti-LY-6G-PE (clone 1A8) and anti-F4/80-AlexaFluor647.
Osteoblast-lineage cells, MSC and endothelial cells were isolated from the endosteum following collagenase digestion of cleaned bone fragments as previously described 6, [23] [24] [25] .
Hematopoietic cells were removed by magnetic depletion using biotinylated lineage antibodies (CD3, CD5, B220, CD11b, Gr-1, Ter119) followed by depletion with MACS beads conjugated to SAV (Miltenyi Biotech). Cells were then stained at 4°C with CD45-APCCy7, CD31-APC, CD51-PE, Sca-1-PECY7, SAV-FITC for wild-type mice or SAV-PB for col2.3Cre + R26R-YFP +/+ mice and sorted on the gating strategy: CD45 -Lin -CD31 bright endothelial cells; CD45 -Lin -CD31 -Sca-1 bright CD51 + MSC, and CD45 -Lin -CD31 -Sca-1 -CD51 + osteoblast lineage cells 6,23-25 .
All antibodies were from BD Pharmingen except CD150-PE (clone TC15-12F12.2) and anti-F4/80-AlexaFluor647 (clone CI:A3-1) from Biolegend. Data were acquired on an LSRII (BD Biosciences) or CyAn (Dako Cytomation) flow cytometers and analyzed following compensation with single color controls using FloJo software (Tree Star, Ashland, OR).
Immunohistochemistry and TRAP enzyme histology
Fixed and decalcified hind limb bones were embedded in paraffin and 5μm sections cut and placed on SuperFrost Plus® slides (Menzel, Germany). Sections were deparaffinized and rehydrated with xylene and graded ethanol and washed in TBS (immunohistochemistry) or deionized water (histology). F4/80 (rat anti-mouse F4/80, AbD Serotec) and osteocalcin For personal use only. on October 28, 2017. by guest www.bloodjournal.org From (rabbit anti-mouse, Alexis Biochemicals, San Diego, USA) immunohistochemical staining was carried out as previously described 26 . Specificity of staining was confirmed by comparison to serial sections stained with matched isotype control antibodies (Rat IgG2b, AbD Serotec and normal rabbit IgG, Santa Cruz, respectively). TRAP staining was performed as previously described 27 . All sections were examined using an Olympus BX-51 microscope with a DP-70 digital camera and DP controller imaging software (Olympus).
Protease concentration
Quantification of active neutrophil elastase (NE) and cathepsin (G) BM fluids using specific chromogenic substrates, and gelatin zymopgraphy to measure matrix metalloproteinase (MMP)-9 was carried out as previously described 28, 29 .
Statistics
Significance levels were calculated using the Student's t-test for colony assays, flow cytometry analyses, and RT-qPCR, or two-way ANOVA followed by Fisher's PLSD post-hoc test for histomorphometric measurements.
RESULTS
HSPC mobilization by G-CSF inhibits endosteal niches for HSC
Administration of G-CSF to skeletally-mature mice increased the number of hematopoietic colony forming cells (CFC), and long-term reconstituting Lin -CD41 -Sca1 + KIT + CD48 -CD150 + HSC 30 in the blood from day 2 of G-CSF administration ( Figure 1A) , reaching a plateau between days 4-6, and rapidly returned to baseline when G-CSF administration was ceased ( Figure 1A ). Endosteal markers of bone formation including the proportion of bone surface lined with osteoblasts (ObS/BS) or newly formed bone matrix (osteoid, OS/BS), all decreased 16-to 18-fold during mobilization but rebounded four days after cessation of G-CSF administration to two-fold above baseline ( Figure 1B ) then continued to decrease until day 21.
Both ObS/BS and OS/BS dropped 40-50% on day 1, and 75% on day 2 of G-CSF administration whereas the number of circulating CFC, Lin -Sca1 + KIT + and long-term reconstituting Lin -CD41 -Sca1 + KIT + CD48 -CD150 + HSC significantly increased in blood only on day 2.
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Messenger RNA for osteoblast-lineage-specific genes including osteocalcin, Runx2/Cbfa1 and osterix 31, 32 were also reduced during G-CSF treatment (Supplementary Figure 1 ). Osteocalcin mRNA decreased 50-fold returning to basal levels 4 days following cessation of G-CSF, paralleling the changes in ObS/BS and OS/BS. In addition, mRNA levels for PTHR1, the receptor for both parathyroid hormone (PTH) and PTH-related protein, which is expressed by osteoblasts, were also decreased 24-fold by G-CSF treatment.
To confirm a functional alteration in bone formation, labeling with the fluorescent calcium chelators calcein and xylenol orange was carried out during G-CSF treatment and recovery. These labels rapidly incorporate into bone being mineralized at the time of injection ( Figure 1C ). Continuous bone formation results in labeling of the bone surface with two lines of calcein (green) alternating with two lines of xylenol orange. Both mineralization and bone formation were strongly reduced on both endocortical (diaphysis) and trabecular surfaces (metaphysis) in G-CSF-mobilized mice compared to controls. In contrast, the outer cortical surface (periosteum), was labeled with well-separated multiple fluorochromes in both G-CSFtreated mice and controls, indicating that the disruption in bone formation induced by G-CSF treatment was restricted to the endosteum (i.e. surfaces in contact with BM). Quantification of calcein labels ( Figure 1D ) revealed that the percentage of bone surfaces on which bone formation occurred (double calcein-labeled bone surface dLS/BS) was significantly reduced by G-CSF treatment from 29±1% to 6±2%. On those few surfaces on which bone formation occurred during mobilization, the mineral apposition rate (MAR), was reduced by 30%.
Together, the endosteal trabecular bone formation rate per unit bone surface (BFR/BS) was reduced by 90% in G-CSF-mobilized mice. In contrast, periosteal mineralization surface (PsMAR) was not affected by G-CSF administration. This confirms that only mineralization by osteoblasts in direct contact with the BM is inhibited during HSPC mobilization.
HSC are supported by cytokines and chemokines produced within specific niches at the endosteum, including KL, Ang-1 and CXCL12. In order to determine whether these cytokines were expressed by osteoblasts, we sorted endosteal cells into: i) CD45 -Lin -CD31 bright endothelial cells, ii) CD45 -Lin -CD31 -Sca-1 bright CD51 + multipotent stromal cells (MSC) with osteogenic, chondrogenic and adipogenic potential 24, 25 , and iii) CD45 -Lin -CD31 -Sca-1 -CD51 + osteoblast-lineage cells 6, 23, 24 . RT-qPCR for osteocalcin and the endothelial cell marker VE-cadherin validated this sorting strategy ( Supplementary Figure 2 ). This strategy was further validated by analyzing these 3 populations from col2.3Cre + R26R-YFP +/+ mice in which a Cre-inducible yellow fluorescent protein (YFP) reporter is activated only in maturing and mature osteoblasts 33 . In these mice, 38±13% of cells (n=3 mice) in the osteoblast gate were YFP + , while only 5±1% of cells in MSC gate were YFP + , and YFP + cells were undetectable in the endothelial gate ( Supplementary Figure 2 ).
We then evaluated expression of CXCL12, KL and Ang-1 in endothelial, MSC, and osteoblast-lineage cells by RT-qPCR ( Figure 1E ). CXCL12, a chemokine necessary for HSPC retention in the BM 34, 35 and HSC survival and proliferation 36 was expressed at high levels by osteoblast-lineage cells and at much lower levels by MSC and endothelial cells. Ang-1, a cytokine essential to HSC development 2 was also transcribed by both osteoblast-lineage cells and MSC. Finally KL, a cytokine that acts on all hematopoietic progenitors and HSC, was transcribed by both osteoblast-lineage cells and endothelial cells. These mRNAs were all expressed at much higher levels in endosteal cells compared to the whole BM population ( Figure 1E ). Importantly during G-CSF administration, mRNA levels of CXCL12, KL and Ang-1 were all significantly decreased at the endosteum ( Figure 1F ). In contrast, expression of fibronectin, an extracellular matrix protein produced by BM stromal cells, remained unaltered. Taken together these observations demonstrate that the expression of HSC-trophic cytokines are decreased within the endosteum during mobilization suggesting impaired niche function.
HSPC mobilization is not mediated by osteoclasts
To determine whether osteoclasts were involved in the HSC mobilization and osteoblast inhibition, histochemical staining for tartrate-resistant acid phosphatase (TRAP) and histomorphometry of trabecular bone both showed that the number of osteoclasts on endosteal surfaces (NOc/BPm) was not significantly altered during G-CSF administration (Figure 2A-B ). mRNA for cathepsin K, a marker of active osteoclasts, increased 10-fold, but only 4 days after cessation of G-CSF administration ( Figure 2C ), indicating that any increase in osteoclast number or activity occurs only after HSPC mobilization ceased. The loss of mature osteoblasts during G-CSF treatment and egress of HSPC to blood is therefore unlikely to be dependent on osteoclast depletion; in fact, the normal coupling between osteoclast number and osteoblast number appears to be disrupted during G-CSF administration.
To confirm whether osteoclasts are necessary for G-CSF-induced mobilization of HSPC, osteoclasts were inhibited with zoledronate 37,38 prior to and during G-CSF mobilization. As expected, zoledronate treatment dramatically decreased endosteal osteoclast numbers and did not prevent the reduction in osteoblast numbers in G-CSF-mobilized mice ( Figure 2D -E). Mice treated with zoledronate and G-CSF showed enhanced mobilization of CFC into blood and spleen compared to mice mobilized with G-CSF alone ( Figure 2F-G) which was accompanied by a greater reduction in ObS/BS ( Figure 2E ). Zoledronate alone did not induce mobilization (not shown). To determine whether repopulating HSPC were also mobilized, we performed competitive repopulation assays with the mobilized blood samples.
Blood from individual C57BL/6 CD45.2 + mice were pooled in equal volume within each treatment group, and 50µL of pooled blood was mixed with 200,000 competing BM cells from untreated congenic CD45.1 + mice and transplanted into lethally irradiated CD45.1 + hosts. After transplant, zoledronate significantly increased multi-lineage chimerism from mobilized CD45.2 + blood HSC ( Figure 2H ). Taken together, our data confirm that osteoclasts are not required for HSPC mobilization or the osteoblast suppression associated with mobilization.
G-CSF mobilization disrupts endosteal osteomac and BM macrophage distribution
F4/80 + osteomacs reside in osteal tissues and are intercalated and/or associated with other bone lining cells 26 . These osteomacs form a canopy over mature osteoblasts at sites of bone formation ( Figure 3B ), support osteoblast function in vitro and are required for maintenance of osteoblasts in vivo 26 . Since macrophages 39 , but not osteoblasts 16, 23 express GCSFR, osteomacs were investigated as a candidate mediator of G-CSF effects on osteoblasts. We found F4/80 + osteomacs were reduced on endosteal surfaces from day 2 of G-CSF administration ( Figure 3C ). This reduction was accompanied by a clustering of F4/80 + cells in the central BM, particularly around endothelial sinuses. Between days 4 and 6 of mobilization, F4/80 + cells at the endosteum were virtually undetectable ( Figure 3D ). F4/80 + cells within the endosteal region were detected again 2 days after cessation of G-CSF administration ( Figure 3E ). The osteomac canopy over cuboidal osteoblasts on endosteal surfaces was fully restored by day 10 ( Figure 3F ). Thus, the kinetics of osteomac loss parallels the loss of endosteal osteoblasts in the same animals (Figure 1) .
In vivo depletion of myeloid cells in Mafia transgenic mice deregulates endosteal niches and mobilizes HSPC
To determine the contribution of BM and endosteal macrophages to the regulation of endosteal niches, we ablated c-fms expressing cells, which include most mature myeloid cells such as macrophages and granulocytes, in Mafia transgenic mice. In these mice, a c-fms promoter induces expression of a transgene containing green fluorescent protein (GFP) and a suicide fusion protein made of the FK506 binding protein and the cytoplasmic domain of Fas.
Systemic administration of AP20187, dimerizes the suicide protein to cause Fas-mediated apoptosis in c-fms-expressing cells 18 . Cells expressing the transgene GFP were assessed in Mafia mouse BM by flow cytometry ( Table 2) . As expected, more than 85% of BM F4/80 + Ly-6G -CD11b + macrophages and 90% Ly-6G + F4/80 -CD11b + granulocytes were GFP + indicating expression of the Mafia suicide transgene in both cell populations. Importantly, the Mafia transgene was not expressed in osteoblast-lineage cells, MSC or BM endothelial cells.
Administration of AP20187 ligand ablated transgene-expressing GFP + CD11b + myeloid cells, Ly-6G + granulocytes and F4/80 + macrophages in the BM (Figure 4A ,B,F) as previously reported 18 . In addition, AP20187 treatment elicited robust CFC mobilization into the blood and spleen (Figure 4C Figure 4F ). Osteoclasts, assessed by TRAP staining, were moderately decreased at day 5 (data not shown). None of these effects were observed in wild-type mice treated with AP20187 ligand (Figure 4A -F) demonstrating that this drug is not toxic for myeloid cells, HSPC or mature osteoblasts in the absence of the Mafia transgene. These results suggest that macrophage depletion alone is sufficient to alter endosteal HSC niches and lead to HSC mobilization into blood.
In vivo depletion of phagocytes with clodronate-loaded liposomes disrupts endosteal niches and mobilizes HSPC
The mafia mouse model is not ideal as G-CSF concentration increases in blood during depletion and other myeloid cells are depleted in addition to macrophages. Our data were confirmed in a second mechanistically unrelated model of macrophage depletion in vivo. Mice were injected intravenously with clodronate-loaded liposomes (clo-lip), control PBS-loaded liposomes (PBS-lip), or saline for 1-4 days. Clo-lip treatment (but not PBS-lip) specifically kills phagocytes, the only cells capable of engulfing liposomes 19, 40 . Although BM contains multiple monocyte/macrophage/granulocyte populations, only some were depleted following Clo-lip administration. Specifically, a macrophage population with the unusual F4/80 + Ly-6G + CD11b + phenotype was reduced by 95% within 24 hours of clo-lip administration and remained depleted throughout clo-lip treatment ( Figure 5A ). Interestingly, BM granulocytes (Ly-6G + F4/80 -CD11b + ) were not affected by clo-lip administration until later time-points (4 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From days), when their numbers eventually increased 2.5-fold above baseline. As a control, BM T cell numbers remained unaltered during clo-lip administration (not shown).
Depletion of phagocytic macrophages in the BM by clo-lip administration elicited significant mobilization of CFC and phenotypic Lin -Sca1 + KIT + HSPC within 24h ( Figure   5B ). While no long-term competitive repopulating HSC capable of multi-lineage engraftment were detected in the blood of control PBS-lip injected mice, blood transplantation revealed the presence of circulating long-term competitive repopulating HSC after 2 days of clo-lip administration ( Figure 5C ) with multi-lineage engraftment in 5 of 6 recipients (Fisher exact test p=0.008), and after 4 days of clo-lip, multi-lineage engraftment was observed in 7 of 7 recipients (Fisher exact test p=0.0006). Blood chimerism from mice mobilized with clo-lip for 4 days was 90% in recipients compared to 29±13% donor chimerism when donor mice were mobilized with G-CSF for 3 days ( Figure 2H ).
Administration of clo-lip also dramatically down-regulated osteocalcin, CXCL12, KL
and Ang-1 mRNA in the BM over 10-fold within 24 hours, reflecting rapid disruption of niche function when BM phagocytic macrophages were ablated ( Figure 6A ).
Immunohistochemistry showed severe depletion of endosteal osteomacs in the secondary spongiosa of the metaphysis within 24 hours of clo-lip administration ( Figure 6B ) and flattened morphology of osteocalcin-positive osteoblasts followed by osteoblast depletion at day 2 of clo-lip administration ( Figure 6B ). This time-course of depletion in osteoblast number, and bone formation after clo-lip administration was confirmed by histomorphometry ( Figure 6C ). TRAP staining and histomorphometry also confirmed a decrease in osteoclast number and function within 2 days of clo-lip administration ( Supplementary Figure 3) .
Loss of osteoblasts with clo-lip treatment is not mediated by mature granulocytes or their proteases
Granulocytes can release proteases such as neutrophil elastase (NE), cathepsin G (catG) and matrix metalloproteinase (MMP)-9, which cleave and inactivate the interactions maintaining HSPC within the BM, thereby initiating mobilization 20, 29, 41, 42 . As 4 days of clo-lip treatment lead to an increase in Ly-6G + F4/80 -CD11b + granulocytic-lineage cells in the BM ( Figure 5A Figure 5A ), and increased HSPC mobilization ( Figure 5B-C) . The absence of significant BM protease activity during the first 2 days of clo-lip administration suggests that release of NE, catG and MMP-9 in the BM is not the primary factor inhibiting osteoblast function in response to clo-lip.
In addition, a reduction in osteoid surface and osteoblast number in response to G-CSF in DPP1-deficient mice, which mobilize normally in response to G-CSF despite complete absence of active NE and catG 43 , confirmed that NE and catG are not necessary for osteoblast inhibition in response to G-CSF ( Figure 7C ).
Finally, using GCSFR KO mice, which have very few functional granulocytes and almost no neutrophil protease activity ( Figure 7E ), clo-lip administration still elicited HSPC mobilization ( Figure 7D ) concomitant with osteoblast and osteomac depletion ( Figure 7F and G). Altogether, these data show that CFC mobilization and loss of osteoblasts in response to macrophage depletion or G-CSF treatment is not initiated by proteases released from mature granulocytes in the BM.
DISCUSSION
Cells of the osteoblast-lineage are essential for maintenance of HSC in the BM 8-12 producing cytokines, chemokines and cell-adhesion molecules that regulate HSC fate, including CXCL12, KL, Ang-1 and osteopontin. G-CSF administration transiently suppressed these cells leading to pronounced decreases in bone formation and mineralization at the endosteum, and reduced expression of CXCL12, KL and Ang-1 in the BM. This inhibition of endosteal niches coincided with mobilization of HSC and was not mediated by osteoclasts, but by a loss of osteoblast-supportive osteomacs and/or other phagocytic macrophages with an unusual F4/80 + Ly-6G + CD11b + phenotype. Indeed, in vivo depletion of macrophages in two mechanistically unrelated models, depleted osteoblasts and HSC niche function causing robust HSPC mobilization into the blood. These data demonstrate that BM macrophages play a critical role in the maintenance of endosteal HSC niches in vivo.
Since osteoblasts do not express G-CSFR, the mechanisms of G-CSF-mediated osteoblast suppression must be indirect 16, 23 , and a number of mediators have been proposed.
Although adrenergic receptors are involved in HSPC mobilization in response to G-CSF 16 ,
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From they are clearly not the only players. In mice knocked-out for both β 2 and β 3 adrenergic receptors, HSPC mobilization in response to G-CSF was reduced by only 50% 44 .
Furthermore, treatment with the β adrenergic antagonist propanolol in WT adult mice reduced G-CSF-induced HSPC mobilization by only 30% 16 . BM leukocytes also play an important role in osteoblast regulation. Indeed in G-CSFR KO to WT transplantation chimeras, where nerve and BM stromal cells express G-CSFR but donor BM leukocytes do not, CFC are no longer mobilized in response to G-CSF nor are osteoblasts suppressed 17 . Therefore BM leukocytes are critical to both endosteal osteoblast suppression and HSPC mobilization.
Osteoclasts have also been reported to play a role in HSPC mobilization by secreting cathepsin K, which cleaves and inactivates CXCL12 and KL 45 . These conclusions were drawn from experiments at a single time point of G-CSF mobilization. However, our data clearly demonstrate that neither osteoclast number nor cathepsin K transcription is increased during the initiation of G-CSF-mediated HSC mobilization. In fact a rise in osteoclasts and cathepsin K occurs subsequently when mobilization is over (herein and ref14). Furthermore, osteoclast inhibition with the potent bisphosphonate zoledronate did not inhibit, but enhanced mobilization of CFC and competitive repopulating cells. We now have congruent data from two inbred mouse strains demonstrating that i) osteoclast numbers and bone degradation increase only after cessation of G-CSF treatment and ii) that bisphosphonates (zoledronate or pamidronate 15 ) synergize with G-CSF to increase CFC mobilization. Additionally in the two macrophage-depletion models used here, osteoclast numbers were reduced as a result of the depletion strategies, yet robust HSC mobilization occurred. Hence, we conclude that osteoclasts and release of cathepsin K are not the prime initiators of osteoblast suppression and HSC mobilization in response to G-CSF.
Tissue macrophages are phenotypically and functionally diverse, some sub-populations have trophic roles specific to their resident tissue, particularly in tissue development 46 and wound healing 47 . BM contains at least two trophic resident macrophage populations: central BM macrophages and endosteal osteomacs 26 . Central BM macrophages are located throughout the BM stroma and often cluster with erythroid precursors to support erythropoiesis 48 . More recently we described osteomacs, which support osteoblast function and maintain bone forming surfaces in vivo 26 . We now provide evidence that BM macrophage populations are also essential for the maintenance of the endosteal HSC niche. Furthermore, their depletion results in loss of endosteal osteoblasts, down-regulation of CXCL12, KL and Ang-1 mRNA at the endosteum, and mobilization of HSPC into the blood. 
Data are average ± SD of 3 mice. Wild-type mice had no cells (less than 0.05%) expressing GFP. 
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